Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid New M&A Rumors, Amarin CEO Focused On Vascepa Approval

Pfizer and Gilead Seen As Suitors

Executive Summary

 John Thero insists company is focused on approval and launch, as interest in European rights grow.

You may also be interested in...



Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss

A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.

Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain

First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.

New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market

The addressable patient population in the US could increase by 4.5 million if new trial is successful.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel